Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new ...

These results correspond to an 80% reduction in the risk of death among patients surviving beyond five years.

A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results. This is an ASCO Meeting ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

or on the link below. Targeting the androgen receptor by depriving testosterone with gonadotropin-releasing hormone agonists or antagonists, or surgical castration, has been the backbone of metastatic ...

Researchers tested opaganib in combination with standard hormone therapies in men with resistant prostate cancer. They ...

Primary Mediastinal Germ Cell Tumors: A Real-World Analysis of Clinical Characteristics, Treatment, and Survival Outcomes From Two Tertiary Cancer Centers in India Abiraterone acetate (AA) is approved ...

Schoolcraft Memorial Hospital, in collaboration with Green Bay Oncology, has launched a new Nuclear Medicine service line offering Pluvicto (lutetium Lu-177 vipivotide tetraxetan), an FDA-approved ...

Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with mCSPC ...

In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...

FORT MYERS, Fla., Jan. 22, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is among the first oncology providers in Florida selected to enroll patients in a phase 3 ...